RY

Koninklijke Philips NVOOTC RYLPF Stock Report

Last reporting period 30 Jun, 2024

Updated 01 Nov, 2024

Last price

Market cap $B

28.769

Large

Exchange

OOTC - OTC

RYLPF Stock Analysis

RY

Avoid

Based on Eyestock quantitative analysis, RYLPF`s fundamental data and valuation indicate an investment grade of Avoid at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

34/100

Low score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-25.5 %

Greatly overvalued

Market cap $B

28.769

Dividend yield

3.61 %

Shares outstanding

881.48 B

Koninklijke Philips NV is a technology company, which engages in the healthcare, lighting, and consumer well-being markets. The company is headquartered in Eindhoven, Noord-Brabant and currently employs 77,233 full-time employees. The company went IPO on 2009-09-18. The firm's segments include Personal Health businesses, Diagnosis & Treatment businesses, Connected Care & Health Informatics businesses, HealthTech Other and Legacy Items. The Personal Health businesses segment is engaged in the health continuum, delivering integrated, connected solutions that support healthier lifestyles and those living with chronic disease. The Diagnosis & Treatment businesses segment delivers precision medicine and treatment, and therapy. The Connected Care & Health Informatics businesses segment provides consumers, care givers and clinicians with digital solutions that facilitate care by enabling precision medicine and population health management. The HealthTech Other segment comprises such items, as innovation, emerging businesses, royalties, among others. The Legacy Items segment consists mainly of separation costs, legacy legal items, legacy pension costs, among others.

View Section: Eyestock Rating